Description: Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases. Its strategic brands include ACTIKERALL, BALNEUM, DECODERM, SATIVEX, SKILARENCE, and DECODERM. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as drug discovery partnership with X-Chem, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Home Page: www.almirall.com
Ronda General Mitre, 151
Barcelona,
08022
Spain
Phone:
34 93 291 30 00
Officers
| Name | Title |
|---|---|
| Mr. Carlos Gallardo Piqué | CEO, President, Member of Management Board & Chairman of the Board |
| Mr. Michael McClellan | CFO & Member of Management Board |
| Mr. Eloi Crespo Cervera | Chief Industrial Operations Officer & Member of Management Board |
| Mr. Esteve Conesa Panicot | Chief People & Culture Officer and Member of Management Board |
| Dr. Volker Koscielny | Chief Medical Officer & Member of Management Board |
| Dr. Karl Ziegelbauer | Chief Scientific Officer & Member of Management Board |
| Mr. Paolo Cionini | Chief Commercial Officer Europe & International and Member of Management Board |
| Ms. Isabel Cristina Gomes | Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board |
| Ms. Mercedes Diz Lopez | Chief Marketing Officer & Member of Management Board |
| Mr. Paul Rittman | Member of Management Board and President & GM of Almirall US |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 15.873 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2692 |
| Price-to-Sales TTM: | 2.0518 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1904 |